JP Morgan: Witty Happy To Be 'Promiscuous' To Rebuild GSK's Oncology Presence

Andrew Witty has taken a lot of flak over the past couple of years as GlaxoSmithKline Plc. lurched from one 'challenge' to another – from the bribery scandal in China and corruption allegations elsewhere, to a string of late-stage product failures, to a less than stellar uptake of its new respiratory franchise. But things are now on a steady footing and the UK-based pharma major is entering a growth phase, if the CEO's comments at the 34th annual JP Morgan Healthcare Conference on Jan. 13 are to betaken at face value.

Andrew Witty has taken a lot of flak over the past couple of years as GlaxoSmithKline Plc. lurched from one 'challenge' to another – from the bribery scandal in China and corruption allegations elsewhere, to a string of late-stage product failures, to a less than stellar uptake of its new respiratory franchise. But things are now on a steady footing and the UK-based pharma major is entering a growth phase, if the CEO's comments at the 34th annual JP Morgan Healthcare Conference on Jan. 13 are to betaken at face value.

At GSK's R&D update in November, rather a lot of incremental information on pipeline candidates was provided. Below, Scrip...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anti-infective

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?